Lead by proven industry experience, Marvel is at the forefront of modern science.

We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.

The Company has been specifically focused on the discovery of new chemical entities that inhibits the A2a adenosine receptor. The A2a receptor is a target for a number of diseases representing areas of significant unmet medical needs, each with multi-billion dollar potential, and with fundamentally no competitors.

Our drug assets are targeted for the treatment of large and growing markets associated with a predominantly aging population.

 

The Company is targeting specifically

Neurological Diseases
that have not been treated with
conventional therapeutics

Non-Alcoholic
Steatohepatitis (NASH)
Currently no approved therapies

Cancer
Pursuing as an adjunctive
therapy

Stock Information

 

Shares Outstanding : 39,786,231
Insider Ownership : 13,575,098 (34.1%)
Stock options granted : 3,350,000

Corporate Factsheet

Marvel Factsheet Download

 

 

 

 

Recent News

Marvel Biosciences Announces Non-Brokered Private Placement

Calgary, Alberta, Canada, January 19, 2024 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce the Company has closed a non-brokered private placement (the...

Contact

Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2

(403) 770-2469

 

Marvel Biosciences

Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.

Email Us

8 + 2 =